Skip to main content
. 2018 Oct 30;266(1):57–67. doi: 10.1007/s00415-018-9092-4

Fig. 4.

Fig. 4

a Natural killer- (NK-) cells (CD56brightCD16+) and T helper -cell subsets in rituximab (RTX) treated MS vs. RRMS without RTX, and healthy controls [4]. b Regulatory T-cells (CD4+CD25+ FoxP3+), c Th1-cells (CD4+ IFNγ+)